@Mason14, so no right of reply over there after you asked me???? Why isn't your post being moderated because of "Off topic"??
Again, CHECKvacc clinical trial was superseded by the VAXINIA clinical trial as mentioned in their Q3 2023 quarterly.
YF published a medical journal of a case study (https://pmc.ncbi.nlm.nih.gov/articles/PMC10640805/) of a TNBC patient who received a dosage of 1×10^5 PFU and achieved CR which was why the clinical trial for VAXINIA started but is opened to all solid cancer with a low dosage of 1×10^6 PFU using the data gathered from the CHECKvacc.
The clinical trial update for VAXINIA released 14 months ago was excellent and why IMU received Fast Track designation within only 12-16 months of the clinical trial which is quite quick given the data demonstrated efficacy so early in the clinical trial. "Baseless" ramping is saying the MC will be $5B at the end of Ph1 clinical trial as that's when BP will make their move since there will be enough data to demonstrate efficacy, we already know CF33 has an excellent safety profile and BP usually do T/O for IP which has a commercial viability and valuation (I don't see this with RC220 as previously mentioned) at the end of Ph2 clinical trial since that's when efficacy is seen for Ph3 clinical trial so is it "baseless"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)